Abstract:Highlights • l -THP was successfully incorporated into CD-MOF and significantly improved solubility for pulmonary delivery. • DPI formulation of l -THP, such as SV010- l , possessed excellent aerosolization with an FPF of 37.25%. • The bioavailability of l -THP and its primary bioactive metabolites via inhalation administration were significantly improved in rats. Levo-tetrahydropalmatine ( l -THP), an active ingredient used to treat lung injury, shows limited therapeutic potential due to its poor solubility and low absorption. This study uses γ-cyclodextrin metal-organic frameworks (CD-MOFs) with particle sizes of 1–5 μm to encapsulate l -THP to form inhalable l powders that simultaneously improve the solubility and facilitate pulmonary delivery. Characterization analysis and in vitro deposition of the powders were carried out using scanning electron microscopy (SEM), powder X-ray diffractometry (PXRD), next-generation impactor (NGI), etc. The perfect aerosolization was achieved with a fine particle fraction (FPF) of 37.25 ± 2.80% when the powders were formulated with lactose (SV010). The results showed that l particles were eliminated much faster than l -THP in rat liver microsomes (RLuM) and rat lung microsomes (RLiM) medium. Compared to the oral administration in vivo , the AUC 0–24h and C max of l -THP via inhaling SV010- l CD-MOF powders increased by approximately 85- and 37-folds, respectively. Moreover, the AUC 0–24h of its metabolites, including l -isocorypalmine (L-ICP) and l -corypalmine (L-CP) were also increased apparently. In conclusion, the dry powder inhaler (DPI) of l -THP was delivered efficiently to the lungs and significantly improved the bioavailability of l -THP and its active metabolites in vitro and in vivo , which may make l -THP a promising treatment for a wide range of respiratory diseases. Graphical abstract l -THP was successfully loaded in CD-MOF to form DPI formulation. The bioavailability of l -THP and its active metabolites, L-ICP and L-CP via pulmonary deliver were significantly improved in rats. Download : Download high-res image (161KB) Download : Download full-size image

Co-achievement of enhanced absorption and elongated retention of insoluble drug in lungs for inhalation therapy of pulmonary fibrosis

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

Simultaneous solubilization and extended release of insoluble drug as payload in highly soluble particles of γ-cyclodextrin metal-organic frameworks

Glycyrrhetinic acid loaded in milk-derived extracellular vesicles for inhalation therapy of idiopathic pulmonary fibrosis

Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: fabrication, characterization, pharmacokinetics, and pharmacodynamics

Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease

Inhalable FN-binding liposomes or liposome-exosome hybrid bionic vesicles encapsulated microparticles for enhanced pulmonary fibrosis therapy

Paeonol loaded cyclodextrin metal-organic framework particles for treatment of acute lung injury via inhalation

Preparation and evaluation of sustained release pirfenidone-loaded microsphere dry powder inhalation for treatment of idiopathic pulmonary fibrosis

Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis

Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery

Highly efficient pulmonary delivery of levo-tetrahydropalmatine using γ-cyclodextrin metal-organic framework as a drug delivery platform

Solidification of volatile D-Limonene by cyclodextrin metal-organic framework for pulmonary delivery via dry powder inhalers: In vitro and in vivo evaluation

Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol–Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties

Ciprofloxacin nanocrystals and N-acetylcysteine co-solidified powders for pulmonary drug delivery: development and in vitro and in vivo characterization

A Two‐Pronged Pulmonary Gene Delivery Strategy: A Surface‐Modified Fullerene Nanoparticle and a Hypotonic Vehicle

Customizable resveratrol spray-dried micro-composites for inhalation as a promising contender for treatment of idiopathic pulmonary fibrosis

Preparation of Ibuprofen-Loaded Inhalable γCD-MOFs by Freeze-Drying Using the QbD Approach

Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis

Comprehensive In Vitro and In Silico Aerodynamic Analysis of High-Dose Ibuprofen- and Mannitol-Containing Dry Powder Inhalers for the Treatment of Cystic Fibrosis

Dandelion inspired microparticles with highly efficient drug delivery to deep lung